Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access of Deferasirox for Chronic Iron Overload
NCT00235391Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in hemochromatosis (HH), sponsored by Novartis. Primary endpoint: Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events up to 104 weeks. Started Oct 2005; status: completed.
02
Drugs
deferasirox
03
Conditions
hemochromatosis (HH)
Beyond the preview
Go deeper on NCT00235391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00235391.